Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting

Volumn 35, Issue , 2016, Pages e324-e335

  Mesa, Ruben A ^a   Passamonti, Francesco ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

11-(2-PYRROLIDIN-1-YLETHOXY)-14,19-DIOXA-5,7,26-TRIAZATETRACYCLO(19.3.1.1(2,6).1(8,12))HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE; ADENYLATE KINASE; ADENYLATE KINASE 2; BENZAMIDE DERIVATIVE; BRIDGED COMPOUND; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PYRIMIDINE DERIVATIVE;

ALLOTRANSPLANTATION; GENETICS; HUMAN; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY; PERSONALIZED MEDICINE; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; STEM CELL TRANSPLANTATION; THROMBOCYTHEMIA, ESSENTIAL;

ADENYLATE KINASE; BENZAMIDES; BRIDGED-RING COMPOUNDS; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRECISION MEDICINE; PRIMARY MYELOFIBROSIS; PYRIMIDINES; STEM CELL TRANSPLANTATION; THROMBOCYTHEMIA, ESSENTIAL; TRANSPLANTATION, HOMOLOGOUS;

EID: 85020309163     PISSN: None     EISSN: 15488756     Source Type: Journal    
DOI: 10.14694/EDBK_159322     Document Type: Review

References (0)